Mayo Clinic licenses vaccine tech to TapImmune for all HER2/neu cancers

breast cancer
Breast cancer cells--Courtesy of National Cancer Institute

TapImmune, which focuses on infectious diseases and immuno-oncology, has chosen a tricky field, as cancer vaccines have seen limited success. But the biotech pushes on, licensing Mayo Clinic's HER2/neu vaccine technology to develop vaccines for any cancer where the HER2/neu gene is overexpressed.

Mayo Clinic initially licensed the technology to Jacksonville, FL’s TapImmune in 2012, for the development of a vaccine to treat HER2/neu breast cancer. That candidate has undergone Phase I trials, reporting positive safety and immune response data in June 2015. The company plans to bring it into Phase II trials at the beginning of 2017, it said in a statement Tuesday. While CEO Glynn Wilson said the candidate could be developed as a standalone vaccine or as part of a combination approach, he did not disclose any other cancers the company plans to target using Mayo Clinic’s platform.

The duo is also collaborating on a folate receptor alpha vaccine for patients with triple-negative breast cancer. These patients have no treatment options other than chemotherapy and surgery, but Wilson thinks TapImmune’s vaccine could work in 90% of women, compared to current vaccines that work in about 20% of women. TapImmune does not currently have any products on the market.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

TapImmune is working with AstraZeneca ($AZN) on a combination therapy for ovarian cancer, comprising the former’s anti-folate receptor vaccine and the latter’s anti-PD-L1 antibody, durvalumab. The treatment will enter Phase II trials this year.  Several high-profile companies, including GlaxoSmithKline ($GSK) and Merck KGaA, have developed cancer vaccines only to run into late-stage failures. But several companies hope combining their vaccines with checkpoint inhibitors like PD-L1 drugs will help realize their potential.

- here's the statement

Related Articles:
Bristol's Opdivo-Yervoy combo ups response rates in first-line lung cancer patients
Mayo Clinic secures $13.3M DOD grant to test TapImmune breast cancer vax
Cancer vaccines field to see sizable growth, report says
Immunotherapy combos could provide a new path forward for troubled cancer vaccine field


Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.